Short-chain fatty acids (SCFAs) with the anti-inflammatory capacity are produced by intestinal bacteria; however, their effect on the acute systematical inflammation remains unclear. This study aimed to investigate the effects of SCFAs, acetate, propionate and butyrate, on septic shock and the underlying mechanism. The LPS-induced septic model was used to evaluate the function of SCFAs by survival rate observation. Only butyrate, but not acetate or propionate, significantly decrease the mortality of septic mice. At 2 h and 6 h of LPS administration, the levels of TNF-a, IL-6 and IL-1b in plasma were measured by ELISA to estimate the effects of butyrate pretreatment on excessive inflammation. And the anti-inflammatory mediators including TGF-b, IL-10 and LXT4 in plasma were detected for further mechanism study in septic mice. Moreover, the murine macrophage-like RAW 264.7 cells were stimulated by LPS to further confirm the finding in vivo. Pretreatment with butyrate led to significant attenuation of the LPS-induced elevation of TNF-a, IL-6 and IL-1b levels. However, when detecting the anti-inflammatory factors, a significant increase in IL-10, but not TGF-b or LXT4, was shown in butyrate-pretreated group. Pretreatment of RAW 264.7 cells with butyrate led to downregulation of LPSinduced pro-inflammatory mediators, IL-6 and IL-1b, but did not affect the level of TNF-a, and increased IL-10 (P < 0.01). In conclusion, SCFA butyrate significantly attenuated the inflammation against sepsis through upregulation of anti-inflammatory IL-10.
Introduction
Sepsis is one of the leading causes of death with an estimated incidence rate of up to 19 million people worldwide every year [1] . Sepsis arises from the host response to infection, which is aimed to clean the invading pathogenic micro-organisms. Therefore, sepsis outcomes are decided not only by the invading pathogen, which can directly destroy the function and structure of tissue, but also even more by the host response, which may be overexcessive and induce self-damages, because it is hard to discriminate between microbial and host targets when the highly potential effectors are activated [2] .
In order to improve therapeutic effects, considerable resources were invested to develop the innovative, alternative sepsis therapies. However, no interventions were successful in the clinical setting although some treatments were identified to improve survival in animal models of sepsis [3, 4] . Activated protein C, commercially named drotrecogin alfa, was the only approved treatment drug specifically for the severe sepsis. However, it was withdrawn from the market in 2011, because of its side effects and uncertain outcomes in the clinical application [2, 5] .
Short-chain fatty acids (SCFAs), acetate, propionate, and butyrate, derived from probiotic microbiota in intestine, are the anti-inflammatory agents that effectively protect rodent animals and human against inflammatory-related injuries [6] [7] [8] [9] [10] . We reasoned that SCFAs might be also protective in sepsis, because the pathogenesis of sepsis also depends on activation of cytokine responses. Herein, we examined the SCFAs effects of mortality on lethal sepsis models caused by LPS, and detected the pro-inflammatory mediators, TNF-a, IL-6 and IL-1b, and anti-inflammatory mediators, TGF-b, IL-10 and LXT4. Only butyrate was effective on sepsis, by reducing mortality and excessive inflammation, and upregulating the expression of IL-10. Here, we found that SCFA butyrate inhibits the excessive inflammation and protects septic mice.
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Ó 2016 The Foundation for the Scandinavian Journal of Immunology Endotoxin Shock. Mice were injected with LPS (30 mg/kg, i.p.) [11] . Blood was collected at 2 h and 6 h after LPS administration, and centrifuged for 20 min at 1500 g. Plasma samples were stored at À80°C for the subsequent analysis. Mortality was continuously recorded for up to 3 days after injection of LPS. Survivors were observed for 3 weeks to ensure that no additional late deaths occurred.
Cell culture. Murine macrophage-like RAW 264.7 cells were cultured in DMEM medium supplemented with 10% FBS, antibiotic mix and 2 mM L-glutamine in a humidified incubator with 5% CO 2 and 95% air. Cultured RAW 264.7 cells with 75% confluence were treated with LPS by a dose of 1 lg/ml alone or pretreated with 100 lM butyrate for 1 h. Afterwards, supernatants were collected and frozen for cytokine examination.
ELISA determination. The plasma of septic mice and conditioned medium from RAW 264.7 cell cultures was collected and prepared to detect TNF-a, IL-6, IL-1b, IL-10 and TGF-b by commercial ELISA kits. All operations conducted followed the manufacturers' instructions.
Real-time PCR. Total RNA was isolated from cultured cells by TRIzol reagent from Beijing ComWin Biotech, Co. (Beijing, China) according to the manufacturer's instruction. The mRNAs for IL-1b, TNF-a, IL-6, TGF-b, IL-10 and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were quantified by real-time PCR using the corresponding primers and the QuantiTect SYBR Green PCR kit from Applied Biosystems, Co. Ltd. (Foster City, CA, USA).
Statistical analysis. Data were expressed as mean AE SD. Statistics were analysed by the Bonferroni test to determine the significant differences between each group. KaplanMeier test was employed to determine the differences in survival rate of groups. A value of P < 0.05 was statistically considered to indicate significance.
Results
Pretreatment with butyrate, not acetate or propionate, prevented lethality of septic mice induced by LPS In order to initially evaluate effect of SCFAs, acetate, propionate and butyrate on systemic inflammation, we employed the classical sepsis models induced by LPS (Fig. 1) . In response to a lethal dose of stimulation, mice in model group were shown high mortality. The LPS-treated group showed a 20% survival rate on the final day. Both of acetate-and propionate-pretreated group displayed no effect on survival rate. But, pretreatment with butyrate significantly increased the survival rate up to about 60%. These results suggested that butyrate pretreatment ameliorated septic shock in mice.
Butyrate attenuated overdose of inflammation and upregulated the level of IL-10 in septic mice challenged by LPS To evaluate the anti-inflammatory role of butyrate in sepsis, the levels of pro-inflammatory cytokines including TNF-a, IL-6 and IL-1b in plasma were detected in our study. The results showed that these pro-inflammatory cytokines significantly increased at 2 h and 6 h in plasma of LPS-challenged mice, compared with control group. However, butyrate obviously reduced the increased cytokines (P < 0.01, n = 6/group, Fig. 2A and B) . ............................................................................................................................................................... TGF-b, IL-10 and LXA4 are the main anti-inflammatory mediators; therefore, we detected their concentration to investigate the underlying mechanism of anti-inflammation for butyrate. The data showed that in contrast to model group, butyrate increased the release of IL-10, but not TGFb or LXA4 (Fig. 2C and D) . Figure 2 The effects of butyrate pretreatment on the inflammation-related cytokines in plasma of 2 h (A) and 6 h (B) after LPS administration. The animals were treated as described in Figure 1 . The plasma was obtained for measuring these indicators using ELISA kits of TNF-a, IL-6, IL-1b, IL-10, TGF-b and LXA4, respectively. The values are expressed as the means AE SD (n = 6). **P < 0.01, compared to the model group.
Pretreatment with butyrate alleviated the LPS-induced inflammation and increased the expression of IL-10 in RAW 246. 7 In order to further identify what we found in the animal experiment, the cultured Raw 246.7 was pretreated with butyrate 3 h prior to LPS stimulation. As shown in Fig. 3A and B, butyrate pretreatment significantly attenuated the increased expression of IL-6 and IL-1b by LPSchallenged mice (P < 0.01). However, butyrate had no effect on the amounts of TNF-a, which has been shown in previous study [12] . And the elevated level of IL-10 in Figure 3 The effects of butyrate pretreatment on the cytokines in Raw 264.7 cells after LPS administration. Raw 264.7 cells were pretreated with 100 lM butyrate 1 h prior to stimulation of LPS (1 lg/ml). .......................................................................................................................................................... .....
butyrate group was also detected (Fig. 3C and D) , consistently with our data shown in animal study. These results suggested the anti-inflammation effects of butyrate in a selective manner on macrophage, and the mechanism is upregulated IL-10 expression.
Discussion
SCFAs, primarily including acetate, propionate and butyrate, are organic acids produced by intestinal bacteria which ferment undigested dietary fibres [13] . SCFAs have been shown anti-inflammation [8] , immune modulation [9] and protection for gastric and intestinal mucosa [14, 15] . In particular, butyrate is considered as the most importance of SCFAs, because it not only acts as an energy source for the epithelial cells, but also influences a wide array of cellular functions in intra-and extra-intestinal organs and systems [16] . Due to the prominently biological functions of SCFAs, we designed this experiment to observe the effect of SCFAs on acute systematical inflammation and the molecule mechanism. In order to screen the effective SCFAs on sepsis, we employed the classical sepsis model induced by LPS, which is widely used to screen potential treatment drugs and study the underlying mechanism for sepsis and its related complications in mice [17, 18] , to observe the survival rate. Herein, we primarily found that only butyrate, but not acetate or propionate, significantly ameliorated mortality. In fact, attenuation of butyrate in liver [19] and lung [20] damage induced by LPS has been reported in previous studies. Currently, we discovered the direct protection of butyrate on sepsis in this study.
Systematical inflammatory reaction initiates a cascade of events such as hypoperfusion, hypotension, multiple organ system dysfunction and even mortality. LPS can induce this severely inflammatory process by stimulating immune cells, especially macrophages [21] , to release amounts of inflammatory mediators such as TNF-a, IL-6 and IL-1b. In consistent with previous studies [22, 23] , TNF-a, IL-6 and IL-1b were deterioratively upregulated by LPS challenge, which was significantly inhibited by butyrate pretreatment in our animal experiment. But, we found TNF-a was not affected by butyrate in cultured macrophage in vitro, as reported by Chang et al [12] . It indicated that butyrate can modulate other immune cells other than only macrophage to inhibit LPSinduced systematical inflammation. In the published papers, butyrate has been reported effective on the inflammationrelated diseases models such as ischaemia/reperfusion of liver [7] and heart [24] , and acute lung injury [20, 25] .
Anti-inflammation is considered as the key mechanism to attenuate inflammatory reaction [26] . Therefore, we detected related parameters and found that IL-10, but not TGF-b or LXA4, was upregulated by butyrate pretreatment, indicating that IL-10 is the butyrate effector for its anti-inflammation. Consistently, in recent studies, it has been reported that butyrate can increase IL-10 level [27] [28] [29] . Butyrate has been well documented for its deacetylase inhibition to regulate gene expression [30] , which may be involved in the upregulation of IL-10 [29] . Moreover, the anti-inflammation of butyrate was also shown via inhibition of NF-jB in some reports [31, 32] . But, recent studies showed that Gpr109a, the special receptor for butyrate, played a critical role in its anti-inflammatory and anticancer function [33] . Therefore, the detail mechanism for butyrate to regulate IL-10 expression, which was not investigated in this study, remains to be deeply studied from these aspects in the next step.
In summary, this study discovered that butyrate protects against sepsis via upregulated IL-10. Moreover, butyrate has been clinically applied for patients with IBD. Therefore, these factors provide a strong rationale suggesting that butyrate can serve as a medical application for treatment of septic patients in the near future.
